News | June 25, 2009

Adult Stem Cell Therapy Treats Previously Untreatable Cardiomyopathy

June 25, 2009 – Six-month follow-up results were released this week for a patient treated with adult stem cells in a clinical study of idiopathic dilated cardiomyopathy, which showed major improvement in cardiac function.

The clinical study is a collaborative effort among physicians at Regenocyte Therapeutic, the American Institute for Regenerative Medicine, and researchers and scientists from TheraVitae.

Leonard Narracci, 71, from Venice, Fla., underwent the adult stem cell therapy in October 2008. Since being diagnosed with idiopathic dilated cardiomyopathy and congestive heart failure, Narracci's ejection fraction was severely reduced at 18 percent (with normal being more than 55 percent). Within three months of the treatment, his ejection fraction improved to 40 percent and is now at 51 percent.

“It goes against traditional theory that we should try to fix damaged heart muscle, but we are generating new heart tissue with impressive results that improve cardiac function and quality of life,” said Leonel Fernandez Liriano, professor of medicine at Pontifical Catholic University School of Medicine (PCUSM) and head of the cardiology team that treated the patient with adult stem cells.

Regenocyte Therapeutic has treated several similar patients who are demonstrating correlative improvements. “We have had success in the ischemic heart disease patients since 2006, and it is encouraging to see that the technology can now be applied to other diseases,” Dr. Grekos said.

For more information: regenocyte.com

Related Content

All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder.

All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder. 

Feature | Structural Heart | March 28, 2019 | Jeff Zagoudis
Structural heart interventions represent one of the fastest growing segments of cardiology, as the number of devices
A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation. Abbott Mitraclip device.

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation.

News | Structural Heart | May 11, 2018
May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial se
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
Overlay Init